|
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS)
|
Mar 2019
|
Leukemia Research
|
myelodysplastic syndromes (MDS)
|
|
A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes
|
Jun 2017
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients
|
Nov 2020
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure
|
Oct 2014
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes
|
Mar 2019
|
Clin Lymphoma Myeloma Leuk
|
myelodysplastic syndromes (MDS)
|
|
A plasma microRNA signature as a biomarker for acquired aplastic anemia
|
Sep 2016
|
Haematologica
|
aplastic anemia
|
|
A Primary Care Approach to Myelodysplastic Syndromes
|
May 2014
|
Korean J Fam Med
|
myelodysplastic syndromes (MDS)
|
|
A promising new treatment for refractory aplastic anemia
|
Jul 2012
|
N Engl J Med
|
aplastic anemia
|
|
A Prospective Multicenter Study of Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure.
|
Oct 2013
|
Cytometry B Clin Cytom
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure.
|
Nov 2013
|
Cytometry B Clin Cytom
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
